收费全文 | 15921篇 |
免费 | 1372篇 |
国内免费 | 40篇 |
医药卫生 | 17333篇 |
2023年 | 119篇 |
2022年 | 84篇 |
2021年 | 429篇 |
2020年 | 256篇 |
2019年 | 404篇 |
2018年 | 397篇 |
2017年 | 324篇 |
2016年 | 359篇 |
2015年 | 399篇 |
2014年 | 537篇 |
2013年 | 763篇 |
2012年 | 1064篇 |
2011年 | 1113篇 |
2010年 | 637篇 |
2009年 | 623篇 |
2008年 | 874篇 |
2007年 | 1014篇 |
2006年 | 880篇 |
2005年 | 856篇 |
2004年 | 836篇 |
2003年 | 792篇 |
2002年 | 760篇 |
2001年 | 277篇 |
2000年 | 272篇 |
1999年 | 246篇 |
1998年 | 167篇 |
1997年 | 149篇 |
1996年 | 121篇 |
1995年 | 127篇 |
1994年 | 105篇 |
1993年 | 120篇 |
1992年 | 142篇 |
1991年 | 162篇 |
1990年 | 177篇 |
1989年 | 153篇 |
1988年 | 151篇 |
1987年 | 145篇 |
1986年 | 123篇 |
1985年 | 126篇 |
1984年 | 103篇 |
1983年 | 93篇 |
1982年 | 80篇 |
1981年 | 65篇 |
1980年 | 58篇 |
1979年 | 76篇 |
1978年 | 75篇 |
1977年 | 65篇 |
1975年 | 43篇 |
1974年 | 50篇 |
1973年 | 38篇 |
Objective
To systematically review literature on uptake and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and/or polio-containing vaccines in infants who were born preterm, with a low birth weight, and/or with chronic health conditions that were diagnosed within the first 6?months of life.Methods
Using a standardized search strategy developed by a medical librarian, records were extracted from MEDLINE, Embase, Database of Abstracts of Reviews of Effects, and CINAHL up to May 8, 2018.Results
Out of the 1997 records that were screened, we identified 21 studies that met inclusion criteria. Eleven studies assessed vaccine coverage and/or timeliness in preterm infants, 6 in low birth weight infants, and 7 in children with chronic health conditions. Estimates of coverage in these populations were highly variable, ranging from 40% to 100% across the vaccines and population groups.Conclusions
There is a lack of studies reporting coverage and timeliness of routine immunizations in special populations of children.Policy implications
Our review suggests a need for improved surveillance of immunization status in special populations of infants, as well as a need for standardization of reporting practices. 相似文献Ultrasound spleen length was also measured in 60 normal control subjects where the upper limit of the 95% reference range was 11.6 cm. Changes in spleen length with both age and body weight were substantial and overshadowed the imperfect reproducibility of this method. Therefore, interpretation of an individual's measured spleen length should be in relation to that predicted for adults of the same age and weight, particularly at the extremes of the younger, heavier patients and also the older, lighter patients.
Ultrasound spleen lengths of different patient groups (21 PP, 26 PT, 17 idiopathic erythrocytosis, 12 secondary polycythaemia, nine apparent polycythaemia) were compared both using the measured overall reference range and the differences from the values predicted for their age and weight. The comparison showed that almost all patients with PP whose spleens were not palpable had spleen lengths greater than the upper limit for the normal control group, but separation from the other patient groups was incomplete.
Detection of non-palpable splenomegaly by ultrasound length should remain a 'minor' criterion amongst the 'proposed modified diagnostic criteria' of PP. 相似文献
Methods: The authors performed a double-blinded, placebo-controlled, multicenter trial to compare the effect of bisoprolol with that of placebo on 1-yr composite outcome including cardiovascular mortality, nonfatal myocardial infarction, unstable angina, congestive heart failure, and cerebrovascular insult. Bisoprolol was given orally before and after surgery for a maximum of 10 days. Adrenergic receptor polymorphisms and safety outcome measures of bisoprolol therapy were also determined.
Results: A total of 224 patients were enrolled. Spinal block could not be established in 5 patients. One hundred ten patients were assigned to the bisoprolol group, and 109 patients were assigned to the placebo group. The mean duration of treatment was 4.9 days in the bisoprolol group and 5.1 days in the placebo group. Bisoprolol therapy reduced mean heart rate by 10 beats/min. The primary outcome was identical between treatment groups and occurred in 25 patients (22.7%) in the bisoprolol group and 24 patients (22.0%) in the placebo group during the 1-yr follow-up (hazard ratio, 0.97; 95% confidence interval, 0.55-1.69; P = 0.90). However, carriers of at least one Gly allele of the [beta]1-adrenergic receptor polymorphism Arg389Gly showed a higher number of adverse events than Arg homozygous (32.4% vs. 18.7%; hazard ratio, 1.87; 95% confidence interval, 1.04-3.35; P = 0.04). 相似文献